Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 3/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.76 |
| ▸ | DPP4 | P27487 | 13/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900202 | 0.90 | KCNA5 (0.73) | KCNA5KCNH2DPP4MAPK8TACR1 | |
| Hydrochloric Acid SCHEMBL2901589 | 0.89 | DPP4 (0.71) | KCNA5KCNH2DPP4MAPK8TACR1 | |
| SCHEMBL2904903 | 0.88 | KCNA5 (0.76) | KCNA5KCNH2DPP4MAPK8TACR1 | |
| SCHEMBL14303480 | 0.88 | KCNA5 (0.76) | KCNA5KCNH2DPP4MAPK8TACR1 | |
| SCHEMBL1382996 | 0.88 | KCNA5 (0.76) | KCNA5KCNH2DPP4MAPK8TACR1 | |
| SCHEMBL3115349 | 0.88 | KCNA5 (0.76) | KCNA5KCNH2DPP4MAPK8TACR1 | |
| SCHEMBL1381998 | 0.88 | KCNA5 (0.76) | KCNA5KCNH2DPP4MAPK8TACR1 | |
| SCHEMBL4686913 | 0.86 | KCNA5 (1.00) | KCNA5KCNH2DPP4MAPK8TACR1 | |
| SCHEMBL1379447 | 0.86 | KCNA5 (0.67) | KCNA5KCNH2DPP4MAPK8TACR1 | |
| Hydrochloric Acid SCHEMBL295443 | 0.85 | KCNA5 (0.98) | KCNA5KCNH2DPP4MAPK8TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322619-B1 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1322619-B1 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-6870055-B2 | Isoquinolinone potassium channels inhibitors | MERCK & CO., INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040044030-A1 | Isoquinolinone potassium channels inhibitors | MERCK SHARP & DOHME CORP. | 2004-03-04 | — | — | US | disclosed |
| EP-1322619-A4 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1322619-A1 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002024655-A1 | ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044030-A1 | Isoquinolinone potassium channels inhibitors | KCNQ5, KCNQ1, KCNQ2 | KCNA5 9/4885KCNH2 6/4885DPP4 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.